Can-Fite Prices $5M Public Offering Of 8.33M ADSs At $0.60/ADS, Plus Warrants To Purchase 16.67M ADSs For Up To $10M More

Author: Benzinga Newsdesk | July 28, 2025 12:28pm
Can-Fite BioPharma Ltd. (NYSE: CANF) (TASE: CANF) ("Can-Fite" or the "Company"), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced the pricing of a public offering with a single institutional investor of 8,333,333 of the Company's American Depositary Shares ("ADSs") (or pre-funded warrants in lieu thereof), together with short-term warrants to purchase up to 16,666,666 ADSs at a combined public offering price of $0.60 per ADS (or pre-funded warrant in lieu thereof) and accompanying short-term warrants. The short-term warrants will have an exercise price of $0.60 per ADS, are exercisable upon issuance and will expire twenty-four months following the date of issuance. The offering is expected to close on or about July 29, 2025, subject to satisfaction of customary closing conditions.

Posted In: CANF